Hannah Choe, MD
Academic Title: Associate Professor in the College of Medicine
Research Program: Leukemia and Hematologic Malignancies
About Me
More info forI am a hematologist who specializes in blood and marrow stem cell transplantation and treating patients with myeloid diseases, including acute myeloid leukemia (AML), myeloproliferative diseases and other conditions requiring allogeneic stem cell transplantation. I received my Doctor of Medicine from Indiana University School of Medicine and then went on to complete my internship and residency in Internal Medicine at the University of Southern California. I completed my fellowship in hematology and medical oncology at Weill Cornell Medical College/New York Presbyterian Hospital. As a member of the Leukemia and Hematologic Malignancies Program at the OSUCCC – James, my research is focused on post-transplant complications, including acute graft versus host disease (aGVHD), a condition that occurs when donor cells attack the recipient. My research investigates new approaches to prevent and better treat aGVHD. In addition to my clinical work, I am an instructor in the Division of Hematology at The Ohio State University and a member of several national organizations, including the American Society of Bone Marrow Transplantation, the American Society of Clinical Oncology and the American Society of Hematology. I also serve as a reviewer for scientific publications such as Biology of Blood and Marrow Transplantation and Leukemia and Lymphoma.
Clinical Expertise
More info for- Hematology
- Graft vs Host Disease
- Acute Myeloid Leukemias
- Leukemia, Myeloid
- Myeloproliferative Disorders
- Stem Cell Transplantation
Where I See Patients
More info forThe Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
460 W. 10th Ave. Columbus, Ohio 43210 800-293-5066 Location InformationEducation & Training
More info forMedical School
- Indiana University School of Medicine-Indianapolis
1800 N Capitol Ave, Indianapolis, IN
Fellowship - Hematology & Oncology
- New York-Presbyterian Hospital
525 E 68Th St, New York, NY
Residency - Internal Medicine
- University of Southern California Medical Center
1441 Eastlake Ave, Los Angeles, CA
- Indiana University School of Medicine-Indianapolis
Academic Office & Contact Information
More info forAcademic Office:
Biomedical Research Tower 0498
460 W 12th Ave
Columbus, Ohio 43210-2210Phone:
614-293-7526Email:
choe.102@osu.eduReviews
More info forPatient Satisfaction Review
The overall patient satisfaction rating is an average of all patient responses to the five questions gathered from the Outpatient Oncology survey, developed by Press Ganey Associates for use in oncology clinics across the country. On behalf of The James, Press Ganey administers the survey to patients who see our providers in an outpatient clinic office. For additional information about the patient satisfaction survey, please visit our
Patient Satisfaction Survey page The comments are submitted by patients and reflect their view and opinions. The comments are not endorsed by and do not necessarily reflect the views of The James.
Publications
More info forOctober 12, 2024Combination ruxolitinib and belumosudil is tolerable and induces responses despite treatment failure as monotherapies.
Caputo J, Peddireddi A, Bhatta S, Huang Y, Bezerra E, Brammer J, Larkin K, Mims A, Vasu S, Wall S, Choe H
Leuk Lymphoma
September 19, 2024Axatilimab in Recurrent or Refractory Chronic Graft-versus-Host Disease.
Wolff D, Cutler C, Lee SJ, Pusic I, Bittencourt H, White J, Hamadani M, Arai S, Salhotra A, Perez-Simon JA, Alousi A, Choe H, Kwon M, Bermúdez A, Kim I, Socié G, Chhabra S, Radojcic V, O'Toole T, Tian C, Ordentlich P, DeFilipp Z, Kitko CL, AGAVE-201 Investigators
N Engl J Med
September 19, 2024Randomized Phase III SIERRA Trial of 131I-Apamistamab Before Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care for Relapsed/Refractory AML.
Gyurkocza B, Nath R, Seropian S, Choe H, Litzow MR, Abboud C, Koshy N, Stiff P, Tomlinson B, Abhyankar S, Foran J, Hari P, Chen G, Al-Kadhimi Z, Kebriaei P, Sabloff M, Orozco JJ, Jamieson K, Silverman M, Van Besien K, Schuster M, Law AD, Larkin K, Pandit-Taskar N, Rowley SD, Munshi P, Cook R, Levy MY, Lazarus HM, Sandmaier BM, Pagel JM, Reddy V, MacDougall J, McNamara K, Spross J, Haeuber E, Vusirikala M, Nahar A, Desai A, Giralt S
J Clin Oncol
September 1, 2024Cutaneous Chronic Graft-Versus-Host Disease: Clinical Manifestations, Diagnosis, Management, and Supportive Care.
Shi CR, Ferreira AL, Kaur M, Xiang D, Caputo J, Choe HK, Hamad N, Cowen EW, Kaffenberger BH, Baumrin E
Transplant Cell Ther
August 16, 2024A Multicenter Phase II Trial of Ruxolitinib for Treatment of Corticosteroid Refractory Sclerotic Chronic Graft-Versus-Host Disease.
Bhatt VR, Shostrom VK, Choe HK, Hamilton BK, Gundabolu K, Maness LJ, Kumar V, Mahato RI, Smith LM, Nishihori T, Lee SJ
J Clin Oncol
July 5, 2024Novel MAGIC composite scores using both clinical symptoms and biomarkers best predict treatment outcomes of acute GVHD.
Akahoshi Y, Spyrou N, Weber D, Aguayo-Hiraldo P, Ayuk FA, Chanswangphuwana C, Choe HK, Eder M, Etra AM, Grupp SA, Hexner EO, Hogan WJ, Kitko CL, Kraus S, Al Malki MM, Merli P, Qayed M, Reshef R, Schechter T, Ullrich E, Vasova I, Wölfl M, Zeiser R, Baez J, Beheshti R, Eng GW, Gleich S, Katsivelos N, Kowalyk S, Morales G, Young R, Chen YB, Nakamura R, Levine JE, Ferrara JLM
Blood
June 12, 2024Impact of chronic graft-versus-host disease on non-relapse mortality and survival.
Jiang J, Sigmund AM, Zhao Q, Elder P, Vasu S, Jaglowski S, Mims A, Choe H, Larkin K, Wall S, Grieselhuber N, William B, Penza S, Benson DM, Efebera YA, Sharma N
Leuk Lymphoma
April 19, 2024Amphiregulin, ST2,and REG3α Biomarker Risk Algorithms as Predictors of Non-Relapse Mortality in Patients with Acute GVHD.
Etra AM, El Jurdi N, Katsivelos N, Kwon D, Gergoudis SC, Morales G, Spyrou N, Kowalyk S, Aguayo-Hiraldo P, Akahoshi Y, Ayuk FA, Baez J, Betts BC, Chanswangphuwana C, Chen YB, Choe HK, DeFilipp Z, Gleich S, Hexner EO, Hogan WJ, Holler E, Kitko CL, Kraus S, Al Malki MM, MacMillan ML, Pawarode A, Quagliarella F, Qayed M, Reshef R, Schechter-Finkelstein T, Vasova I, Weisdorf DJ, Wölfl M, Young R, Nakamura R, Ferrara JLM, Levine JE, Holtan SG
Blood Adv
April 19, 2024The MAGIC algorithm probability predicts treatment response and long-term outcomes to second-line therapy for acute GVHD.
DeFilipp Z, Kim HT, Spyrou N, Katsivelos N, Kowalyk S, Eng GW, Kasikis S, Beheshti R, Baez J, Akahoshi Y, Ayuk FA, Choe HK, Etra AM, Grupp SA, Hexner EO, Hogan WJ, Kitko CL, Qayed M, Reshef R, Vasova I, Zeiser R, Young R, Holler E, Ferrara JLM, Nakamura R, Levine JE, Chen YB
Blood Adv
March 26, 2024A validated risk stratification that incorporates MAGIC biomarkers predicts long term outcomes in pediatric patients with acute GVHD.
Qayed M, Kapoor U, Gillespie S, Westbrook A, Aguayo-Hiraldo P, Francis Ayuk A, Aziz M, Baez J, Choe H, DeFilipp Z, Etra A, Grupp SA, Hexner E, Holler E, Hogan WJ, Kowalyk S, Merli P, Morales G, Nakamura R, Pulsipher MA, Schechter T, Shah J, Spyrou N, Srinagesh HK, Wölfl M, Yanik G, Young R, Kitko CL, Ferrara JLM, Levine JE
Transplant Cell Ther
February 8, 2024A phase II randomized, placebo-controlled, multicenter trial to evaluate the efficacy of cytomegalovirus PepVax vaccine in preventing cytomegalovirus reactivation and disease after allogeneic hematopoietic stem cell transplant.
Nakamura R, La Rosa C, Yang D, Hill JA, Rashidi A, Choe H, Zhou Q, Lingaraju CR, Kaltcheva T, Longmate J, Drake J, Slape C, Duarte L, Al Malki MM, Pullarkat VA, Aribi A, Devine S, Verneris MR, Miller JS, Forman SJ, Aldoss I, Diamond DJ
Haematologica
February 7, 2024Flares of Acute Graft-Versus-Host Disease (GVHD): A Mount Sinai Acute GVHD International Consortium (MAGIC) Analysis.
Akahoshi Y, Spyrou N, Hoepting M, Aguayo-Hiraldo P, Ayuk FA, Chanswangphuwana C, Choe HK, Eder M, Etra AM, Grupp SA, Hexner EO, Hogan WJ, Kitko CL, Kraus S, Al Malki MM, Merli P, Qayed M, Reshef R, Schechter-Finkelstein T, Ullrich E, Vasova I, Wölfl M, Zeiser R, Baez J, Beheshti R, Eng GW, Gleich S, Kasikis S, Katsivelos N, Kowalyk S, Morales G, Young R, DeFilipp Z, Ferrara JLM, Levine JE, Nakamura R
Blood Adv
February 4, 2024A day 14 endpoint for acute GVHD clinical trials.
Spyrou N, Akahoshi Y, Kowalyk S, Morales G, Beheshti R, Aguayo-Hiraldo P, Malki MMA, Ayuk F, Bader P, Baez J, Capellini A, Choe H, DeFilipp Z, Eder M, Eng G, Etra A, Gleich S, Grupp SA, Hexner E, Hoepting M, Hogan WJ, Kasikis S, Katsivelos N, Khan A, Kitko CL, Kraus S, Kwon D, Merli P, Portelli J, Qayed M, Reshef R, Schechter T, Vasova I, Wölfl M, Wudhikarn K, Young R, Holler E, Chen YB, Nakamura R, Levine JE, Ferrara JLM
Transplant Cell Ther
January 16, 2024A randomized phase 2 trial of oral vitamin A for graft-versus-host disease in children and young adults.
Khandelwal P, Langenberg L, Luebbering N, Lake K, Butcher A, Werling K, Ramos KN, Taggart C, Choe HK, Vasu S, Teusink-Cross A, Koo J, Wallace G, Romick-Rosendale L, Watanabe-Chailland M, Haslam DB, Lane A, Davies SM
Blood
January 5, 2024CRISPR/Cas9 deletion of MIR155HG in human T cells reduces incidence and severity of acute GVHD in a xenogeneic model.
Neidemire-Colley L, Khanal S, Braunreiter KM, Gao Y, Kumar R, Snyder K, Weber MA, Surana S, Toirov O, Karunasiri M, Duszynski ME, Chi M, Malik P, Kalyan S, Chan WK, Naeimi Kararoudi M, Choe HK, Garzon R, Ranganathan P
Blood Adv
September 25, 2023Anti-CD3/CD7 immunoconjugate (T-Guard) for severe, steroid-refractory GVHD: final report of BMT CTN 2002.
Meyers G, Hamadani M, Martens M, Ali H, Chevallier P, Choe H, Harris AC, Holler E, van Hooren E, Klaassen W, Leifer E, van Oosterhout Y, Perez L, Pusic I, Stelljes M, van der Velden W, Ammatuna E, Beauvais D, Cornillon J, Maziarz RT, Schetelig J, Romeril J, MacMillan ML, Levine JE, Socié G
Bone Marrow Transplant
July 7, 2023Dupilumab for refractory sclerotic-type cutaneous graft-versus-host disease.
Mital R, Penza SL, Choe HK, Chung CG, Kaffenberger BH
J Eur Acad Dermatol Venereol
May 26, 2023Phase 2 study of natalizumab plus standard corticosteroid treatment for high-risk acute graft-versus-host disease.
Al Malki MM, London K, Baez J, Akahoshi Y, Hogan WJ, Etra AM, Choe HK, Hexner EO, Langston A, Abhyankar SH, Ponce DM, DeFilipp Z, Kitko CL, Adekola KUA, Reshef R, Ayuk FA, Capellini A, Chanswangphuwana C, Eder M, Eng GW, Gandhi I, Grupp SA, Gleich S, Holler E, Javorniczky NR, Kasikis S, Kowalyk S, Morales G, Özbek U, Rösler W, Spyrou N, Young R, Yanik GA, Chen YB, Nakamura R, Ferrara JLM, Levine JE
Blood Adv
May 4, 2023The utility of biomarkers in acute GVHD prognostication.
Spyrou N, Akahoshi Y, Ayuk FA, Holler E, Choe HK, Etra AM, Hogan WJ, Rösler W, Hexner EO, DeFilipp Z, Reshef R, Chanswangphuwana C, Qayed M, Kraus S, Eder M, Javorniczky NR, Grupp SA, Kitko CL, Merli P, Aguayo-Hiraldo P, Wölfl M, Baez J, Beheshti R, Eng G, Gleich S, Katsivelos N, Khan A, Kowalyk S, Morales G, Young R, Nakamura R, Chen YB, Levine JE, Ferrara JLM
Blood Adv
December 27, 2022Three-year outcomes in recipients of mismatched unrelated bone marrow donor transplants using post-transplant cyclophosphamide: follow-up from a National Marrow Donor Program-sponsored prospective clinical trial.
Shaw BE, Jimenez-Jimenez AM, Burns LJ, Logan BR, Khimani F, Shaffer BC, Shah NN, Mussetter A, Tang XY, McCarty JM, Alavi A, Farhadfar N, Jamieson K, Hardy NM, Choe H, Ambinder RF, Anasetti C, Perales MA, Spellman SR, Howard A, Komanduri KV, Luznik L, Norkin M, Pidala JA, Ratanatharathorn V, Confer DL, Devine SM, Horowitz MM, Bolaños-Meade J
Transplant Cell Ther
November 14, 2022Longitudinal Survival Outcomes in Allogeneic Stem Cell Transplantation: An Institutional Experience.
Jiang J, Sigmund AM, Zhao Q, Elder P, Benson DM, Vasu S, Jaglowski S, Mims A, Choe H, Larkin K, Brammer JE, Wall S, Grieselhuber N, Saad A, Penza S, Efebera YA, Sharma N
Cancers (Basel)
September 12, 2022Effective treatment of low risk acute GVHD with itacitinib monotherapy.
Etra AM, Capellini A, Alousi AM, Al Malki MM, Choe HK, DeFilipp Z, Hogan WJ, Kitko CL, Ayuk FA, Baez J, Gandhi I, Kasikis S, Gleich S, Hexner E, Hoepting M, Kapoor U, Kowalyk S, Kwon D, Langston A, Mielcarek M, Morales G, Özbek U, Qayed M, Reshef R, Roesler W, Spyrou N, Young R, Chen YB, Ferrara JL, Levine JE
Blood
July 30, 2022Disease progression, treatments, hospitalization, and clinical outcomes in acute GVHD: a multicenter chart review.
Holtan SG, Yu J, Choe HK, Paranagama D, Tang J, Naim A, Galvin J, Joachim Deeg H
Bone Marrow Transplant
July 16, 2022Characteristics of Graft-versus-Host Disease (GvHD) after Post-transplant Cyclophosphamide versus Conventional GvHD Prophylaxis.
Saliba RM, Majid AA, Pidala J, Arora M, Spellman SR, Hemmer MT, Wang T, Abboud C, Ahmed S, Antin JH, Beitinjaneh A, Buchbinder D, Byrne M, Cahn JY, Choe H, Hanna R, Hematti P, Kamble RT, Kitko CL, Laughlin M, Lekakis L, MacMillan ML, Martino R, Mehta PA, Nishihori T, Patel SS, Perales MA, Rangarajan HG, Ringdén O, Rosenthal J, Savani BN, Schultz KR, Seo S, Teshima T, van der Poel M, Verdonck LF, Weisdorf D, Wirk B, Yared JA, Schriber J, Champlin R, Ciurea S
Transplant Cell Ther
June 23, 2022Disease progression, hospital readmissions, and clinical outcomes for patients with steroid-refractory acute graft-versus-host disease: A multicenter, retrospective study.
Holtan SG, Yu J, Paranagama D, Tang J, Choe HK, Naim A, Joachim Deeg H, Galvin J
Bone Marrow Transplant
January 8, 2022Evaluation of central line salvage for mucosal barrier injury laboratory-confirmed bloodstream infection (MBI-LCBI) management practices in patients with hematologic malignancies.
El Boghdadly Z, Zhao Q, Koutou J, Lustberg ME, Ludwig M, Liscynesky C, Choe H
Leuk Lymphoma
January 1, 2022Impact of Race and Geographic Area of Residence on Outcomes After Allogeneic Stem Cell Transplant.
Sigmund AM, Zhao Q, Jiang J, Elder P, Benson DM, Rosko A, Bumma N, Khan A, Devarakonda S, Vasu S, Jaglowski S, Mims A, Choe H, Larkin K, Brammer J, Wall S, Grieselhuber N, Saad A, Penza S, Efebera YA, Sharma N
Front Oncol
December 21, 2021Acute GVHD, BK hemorrhagic cystitis and age are risk factors for transplant-associated thrombotic microangiopathy in adults.
Vasu S, Bostic MG, Zhao Q, Sharma N, Puto M, Knight S, Scott D, Guzman R, Kromer M, Tackett K, Lind KE, Knill K, Watson E, Wall SA, Saad A, Choe HK, Larkin K, Brammer JE, Jaglowski SM, Penza S, Davies SM, Cataland SR
Blood Adv
November 23, 2021Lessons learned from early closure of a clinical trial for steroid-refractory acute GVHD.
Meyers G, Hamadani M, Martens M, Ali H, Choe H, Dawson P, Harris AC, van Hooren E, Klaassen W, Leifer E, MacMillan ML, van Oosterhout Y, Perez L, Pusic I, Vo P, Levine JE
Bone Marrow Transplant
October 20, 2021New therapeutic targets and biomarkers for acute graft-versus-host disease (GVHD).
Choe H, Ferrara JLM
Expert Opin Ther Targets
September 21, 2021Haploidentical vs. sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia.
Wieduwilt MJ, Metheny L, Zhang MJ, Wang HL, Estrada-Merly N, Marks DI, Al-Homsi AS, Muffly L, Chao NJ, Rizzieri D, Gale RP, Gadalla SM, Cairo MS, Mussetti A, Gore SD, Bhatt VR, Patel SS, Michelis FV, Inamoto Y, Badawy SM, Copelan E, Palmisiano N, Kharfan-Dabaja MA, Lazarus HM, Ganguly S, Bredeson CN, Diaz Perez MA, Cassaday R, Savani BN, Ballen KK, Martino R, Wirk B, Bacher U, Aljurf M, Bashey A, Murthy HS, Yared JA, Aldoss I, Farhadfar N, Liu H, Abdel-Azim H, Waller EK, Solh M, Seftel M, van der Poel MWM, Grunwald MR, Liesveld JL, Kamble RT, McGuirk JP, Munker R, Cahn JY, Lee JW, Freytes CO, Krem M, Winestone LE, Gergis U, Nathan S, Olsson RF, Verdonck LF, Sharma A, Ringden O, Friend BD, Cerny J, Choe HK, Chhabra S, Nishihori T, Seo S, George B, Baxter-Lowe LA, Hildebrandt GC, de Lima M, Litzow MR, Kebriaei P, Hourigan CS, Abid MB, Weisdorf DJ, Saber W
Blood Adv
August 30, 2021Evaluation of elafin as a prognostic biomarker in acute graft-versus-host disease.
Zewde MG, Morales G, Gandhi I, Özbek U, Aguayo-Hiraldo P, Ayuk F, Baez J, Chanswangphuwana C, Choe H, DeFilipp Z, Etra A, Grupp S, Hexner EO, Hogan W, Javorniczky NR, Kasikis S, Kitko CL, Kowalyk S, Meedt E, Merli P, Nakamura R, Qayed M, Reshef R, Rösler W, Schechter T, Weber D, Wölfl M, Yanik G, Young R, Levine JE, Ferrara JLM, Chen YB
Transplant Cell Ther
June 27, 2021Outcomes of Bone Marrow Compared to Peripheral Blood for Haploidentical Transplantation.
Sharma N, Faisal MS, Zhao Q, Jiang J, Elder P, Benson DM, Rosko A, Chaudhry M, Bumma N, Khan A, Devarakonda S, Vasu S, Jaglowski S, Mims AS, Choe H, Larkin K, Brammer JE, Wall S, Grieselhuber N, Saad A, Penza S, Sigmund AM, Efebera YA
J Clin Med
February 4, 2021Effect of Early Post-Transplantation Tacrolimus Concentration on the Risk of Acute Graft-Versus-Host Disease in Allogenic Stem Cell Transplantation.
Sharma N, Zhao Q, Ni B, Elder P, Puto M, Benson DM, Rosko A, Chaudhry M, Devarakonda S, Bumma N, Khan A, Vasu S, Jaglowski S, William BM, Mims A, Choe H, Larkin K, Brammer J, Wall S, Grieselhuber N, Saad A, Penza S, Efebera Y
Cancers (Basel)
January 1, 2021Inhibition of Bromodomain and Extra Terminal (BET) Domain Activity Modulates the IL-23R/IL-17 Axis and Suppresses Acute Graft-Versus-Host Disease.
Snyder KJ, Choe HK, Gao Y, Sell NE, Braunreiter KM, Zitzer NC, Neidemire-Colley L, Kalyan S, Dorrance AM, Keller A, Mihaylova MM, Singh S, Sehgal L, Bollag G, Ma Y, Powell B, Devine SM, Ranganathan P
Front Oncol
December 22, 2020Biomarker-guided preemption of steroid-refractory graft-versus-host disease with α-1-antitrypsin.
Gergoudis SC, DeFilipp Z, Özbek U, Sandhu KS, Etra AM, Choe HK, Kitko CL, Ayuk F, Aziz M, Baez J, Ben-David K, Bunworasate U, Gandhi I, Hexner EO, Hogan WJ, Holler E, Kasikis S, Kowalyk SM, Lin JY, Merli P, Morales G, Nakamura R, Reshef R, Rösler W, Srinagesh H, Young R, Chen YB, Ferrara JLM, Levine JE
Blood Adv
November 24, 2020Comparison of fixed dose reduced-intensity conditioning with fludarabine and busulfan to PK-guided busulfan AUC (FluBu4K) in hematopoietic stem cell transplant for AML/MDS.
Rasor B, Dickerson T, Zhao Q, Elder P, Brammer JE, Larkin K, Jaglowski S, Mims A, Penza S, Vasu S, Wall SA, William B, Saad A, Roddy JVF, Choe H, Puto M
Leuk Lymphoma
October 13, 2020Clinical activity of axicabtagene ciloleucel in adult patients with Richter syndrome.
Kittai AS, Bond DA, William B, Saad A, Penza S, Efebera Y, Larkin K, Wall SA, Choe HK, Bhatnagar B, Vasu S, Brammer J, Shindiapina P, Long M, Mims A, O'Donnell L, Bhat SA, Rogers KA, Woyach JA, Byrd JC, Jaglowski SM
Blood Adv
August 11, 2020American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults.
Sekeres MA, Guyatt G, Abel G, Alibhai S, Altman JK, Buckstein R, Choe H, Desai P, Erba H, Hourigan CS, LeBlanc TW, Litzow M, MacEachern J, Michaelis LC, Mukherjee S, O'Dwyer K, Rosko A, Stone R, Agarwal A, Colunga-Lozano LE, Chang Y, Hao Q, Brignardello-Petersen R
Blood Adv
July 14, 2020Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report.
Zhou Z, Nath R, Cerny J, Wang HL, Zhang MJ, Abdel-Azim H, Agrawal V, Ahmed G, Al-Homsi AS, Aljurf M, Alkhateeb HB, Assal A, Bacher U, Bajel A, Bashir Q, Battiwalla M, Bhatt VR, Byrne M, Cahn JY, Cairo M, Choe H, Copelan E, Cutler C, Damlaj MB, DeFilipp Z, De Lima M, Diaz MA, Farhadfar N, Foran J, Freytes CO, Gerds AT, Gergis U, Grunwald MR, Gul Z, Hamadani M, Hashmi S, Hertzberg M, Hildebrandt GC, Hossain N, Inamoto Y, Isola L, Jain T, Kamble RT, Khan MW, Kharfan-Dabaja MA, Kebriaei P, Kekre N, Khera N, Lazarus HM, Liesveld JL, Litzow M, Liu H, Marks DI, Martino R, Mathews V, Mishra A, Murthy HS, Nagler A, Nakamura R, Nathan S, Nishihori T, Olin R, Olsson RF, Palmisiano N, Patel SS, Patnaik MM, Pawarode A, Perales MA, Politikos I, Popat U, Rizzieri D, Sandmaier BM, Savani BN, Seo S, Shah NN, Uy GL, Valcárcel D, Verdonck LF, Waller EK, Wang Y, Weisdorf D, Wirk B, Wong E, Yared JA, Saber W
Blood Adv
May 17, 2020Risk Factors for Graft-versus-Host Disease in Haploidentical Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide.
Im A, Rashidi A, Wang T, Hemmer M, MacMillan ML, Pidala J, Jagasia M, Pavletic S, Majhail NS, Weisdorf D, Abdel-Azim H, Agrawal V, Al-Homsi AS, Aljurf M, Askar M, Auletta JJ, Bashey A, Beitinjaneh A, Bhatt VR, Byrne M, Cahn JY, Cairo M, Castillo P, Cerny J, Chhabra S, Choe H, Ciurea S, Daly A, Perez MAD, Farhadfar N, Gadalla SM, Gale R, Ganguly S, Gergis U, Hanna R, Hematti P, Herzig R, Hildebrandt GC, Lad DP, Lee C, Lehmann L, Lekakis L, Kamble RT, Kharfan-Dabaja MA, Khandelwal P, Martino R, Murthy HS, Nishihori T, O'Brien TA, Olsson RF, Patel SS, Perales MA, Prestidge T, Qayed M, Romee R, Schoemans H, Seo S, Sharma A, Solh M, Strair R, Teshima T, Urbano-Ispizua A, Van der Poel M, Vij R, Wagner JL, William B, Wirk B, Yared JA, Spellman SR, Arora M, Hamilton BK
Biol Blood Marrow Transplant
Consulting and Related Relationships
More info forAt The Ohio State University Wexner Medical Center, we support a faculty member’s research and consulting in collaboration with medical device, research and/or drug companies because a faculty member’s expertise can guide important advancements in the practice of medicine and improve patient care. In order to provide effective management of these relationships, the university requires annual disclosures from all faculty members with external interests related to their university responsibilities. As of 09/30/2024, Dr. Choe has reported relationships with the companies or entities listed below. If you have questions about the relationships listed below, please ask the faculty member. If you have questions about how these relationships are monitored by The Ohio State University Wexner Medical Center, please contact our Compliance Office.
- Incyte Corporation
- sanofi
- Ironwood Pharmaceuticals
- AbbVie
- Actinium Pharmaceuticals, Inc.
- Regimmune
Patient Comments
I had a successful bone marrow transplant 3 years ago. Dr. Choe has been my doctor throughout the whole process. She is wonderful and I feel I owe my life to her (and other members of the team). She is both brilliant and kind. She answers all of my questions and comes up with solutions for every problem.
There are no hands I would rather be in than the medical staff, nurses, PAs and physicians of the hematology oncology unit on the fifth floor! Especially Dr. Hannah Choe
Dr. Choe has supervised my entire transplant. It's been 2 1/2 years since transplant. She Is so knowledgeable about my condition and has always given me wonderful advise. I come with a list of questions for every visit and she gives me easy to understand directions that answer my questions. She Is always honest and direct. I'm very thankful that Dr. Choe Is my doctor.
NP Jean Caputo and Dr. Choe are both great! Always willing to listen to our concerns & to offer solutions.